We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
Please provide your email address to receive an email when new articles are posted on . Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus ...
MedPage Today on MSN
FcRn Blockers Vie to Become First Approved Drug for Sjogren's Disease
FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...
The neonatal Fc receptor (FcRn) plays a crucial role in maintaining IgG homeostasis by binding to immunoglobulins in a pH-dependent manner. This receptor not only recycles IgG, thereby extending its ...
The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the first approved to ...
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...
A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback